Geron Corp (GERN) stock
GERNNasdaqPharmaceutical PreparationsFiscal year ends December 31
$0.99−0.01 (-0.91%)
Close on Nov 18, 2026Market cap $636.63MP/E –Yield –
Geron operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Geron's operating income for the twelve months ending Jun 30, 2026 was -$51.77M. For fiscal 2025 it was -$68.59M. The highest annual figure on record is -$559.00K in fiscal 2015.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$68.59M | – |
| FY2024 | Dec 31, 2024 | -$173.73M | – |
| FY2023 | Dec 31, 2023 | -$193.94M | – |
| FY2022 | Dec 31, 2022 | -$138.55M | – |
| FY2021 | Dec 31, 2021 | -$114.00M | – |
| FY2020 | Dec 31, 2020 | -$76.91M | – |
| FY2019 | Dec 31, 2019 | -$72.51M | – |
| FY2018 | Dec 31, 2018 | -$31.07M | – |
| FY2017 | Dec 31, 2017 | -$29.26M | – |
| FY2016 | Dec 31, 2016 | -$30.65M | – |
| FY2015 | Dec 31, 2015 | -$559.00K | – |
| FY2014 | Dec 31, 2014 | -$36.31M | – |
| FY2013 | Dec 31, 2013 | -$38.96M | – |
| FY2012 | Dec 31, 2012 | -$71.76M | – |
| FY2011 | Dec 31, 2011 | -$96.12M | – |
| FY2010 | Dec 31, 2010 | -$111.17M | – |
| FY2009 | Dec 31, 2009 | -$70.23M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$12.50M | – |
| Q1 FY2026 | Mar 31, 2026 | $158.00K | – |
| Q4 FY2025 | Dec 31, 2025 | -$25.54M | – |
| Q3 FY2025 | Sep 30, 2025 | -$13.89M | – |
| Q2 FY2025 | Jun 30, 2025 | -$12.45M | – |
| Q1 FY2025 | Mar 31, 2025 | -$16.70M | – |
| Q4 FY2024 | Dec 31, 2024 | -$20.05M | – |
| Q3 FY2024 | Sep 30, 2024 | -$28.22M | – |
| Q2 FY2024 | Jun 30, 2024 | -$69.33M | – |
| Q1 FY2024 | Mar 31, 2024 | -$56.13M | – |
| Q4 FY2023 | Dec 31, 2023 | -$54.29M | – |
| Q3 FY2023 | Sep 30, 2023 | -$47.61M | – |
| Q2 FY2023 | Jun 30, 2023 | -$51.95M | – |
| Q1 FY2023 | Mar 31, 2023 | -$40.09M | – |
| Q4 FY2022 | Dec 31, 2022 | -$41.95M | – |
| Q3 FY2022 | Sep 30, 2022 | -$39.95M | – |
| Q2 FY2022 | Jun 30, 2022 | -$27.98M | – |
| Q1 FY2022 | Mar 31, 2022 | -$28.68M | – |
| Q4 FY2021 | Dec 31, 2021 | -$30.98M | – |
| Q3 FY2021 | Sep 30, 2021 | -$25.67M | – |
| Q2 FY2021 | Jun 30, 2021 | -$28.89M | – |
| Q1 FY2021 | Mar 31, 2021 | -$28.45M | – |
| Q4 FY2020 | Dec 31, 2020 | -$23.27M | – |
| Q3 FY2020 | Sep 30, 2020 | -$20.02M | – |
| Q2 FY2020 | Jun 30, 2020 | -$16.76M | – |
| Q1 FY2020 | Mar 31, 2020 | -$16.87M | – |
| Q4 FY2019 | Dec 31, 2019 | -$30.01M | – |
| Q3 FY2019 | Sep 30, 2019 | -$15.97M | – |
| Q2 FY2019 | Jun 30, 2019 | -$15.22M | – |
| Q1 FY2019 | Mar 31, 2019 | -$11.30M | – |
| Q4 FY2018 | Dec 31, 2018 | -$9.59M | – |
| Q3 FY2018 | Sep 30, 2018 | -$6.81M | – |
| Q2 FY2018 | Jun 30, 2018 | -$7.24M | – |
| Q1 FY2018 | Mar 31, 2018 | -$7.44M | – |
| Q4 FY2017 | Dec 31, 2017 | -$7.79M | – |
| Q3 FY2017 | Sep 30, 2017 | -$7.24M | – |
| Q2 FY2017 | Jun 30, 2017 | -$6.73M | – |
| Q1 FY2017 | Mar 31, 2017 | -$7.49M | – |
| Q4 FY2016 | Dec 31, 2016 | -$8.78M | – |
| Q3 FY2016 | Sep 30, 2016 | -$3.88M | – |
See a number that looks wrong?